Safety and Tolerance of a Partly Fermented Infant Formula With Prebiotic Oligosaccharides in Healthy Infants
NCT ID: NCT03476889
Last Updated: 2018-09-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
252 participants
INTERVENTIONAL
2018-07-19
2021-03-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Randomised, Controlled Study to Assess Safety and Tolerance of Infant Formula With Prebiotics and Postbiotics in Healthy Infants.
NCT04015050
Gastrointestinal Tolerance and Safety of an Infant Formula Containing Prebiotics, Probiotics and Postbiotics.
NCT04745455
Growth and Tolerance of Infants Fed Milk-Based Infant Formula
NCT03967132
Growth of Infants Fed a New Term Infant Formula
NCT03090360
A Clinical Study to Investigate the Effects of an Infant Formula Containing Partially Hydrolysed Proteins on Growth, Safety and Tolerance in Healthy Term Infants
NCT03062761
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Intervention
Cows milk based infant formula containing fermented infant formula and prebiotic oligosaccharides
Infant formula
Infants are randomized to one of two infant formulas from \<14 days of age to 17 weeks of age.
Control
Cows milk based infant formula containing prebiotic oligosaccharides (commercially available Aptamil ProNutra)
Infant formula
Infants are randomized to one of two infant formulas from \<14 days of age to 17 weeks of age.
Breastfed reference
Exclusively breastfed from birth to study completion
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Infant formula
Infants are randomized to one of two infant formulas from \<14 days of age to 17 weeks of age.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Aged ≤14 days at randomisation/enrolment
3. Birth weight within normal range for gestational age and sex
4. Head circumference at birth within normal range for age and sex
5. Maternal age ≥18 years at birth;
6. Intervention arms: exclusively formula fed at randomisation (infants of mothers who autonomously chose not to breastfeed for any reason before their infant is ≤14 days of age, and who intend to exclusively formula feed until their infant is at least 17 weeks of age); OR Breastfed reference arm: exclusively breastfed at enrolment (infants of mothers who intend to exclusively breastfeed until their infant is at least 17 weeks of age);
7. Written informed consent from parent(s) and/or legal guardian(s), who themselves are aged ≥18 years.
Exclusion Criteria
2. Infants known or suspected to have cow's milk allergy, soy allergy and/or lactose intolerance;
3. Infants known or suspected to have current or previous illnesses/conditions or interventions which could interfere with the study or its outcome parameters, as per the clinical judgement of the Investigator;
4. Infants with known or suspected congenital diseases or malformations which could interfere with the study or its outcome parameters (including, but not limited to: GI malformations, congenital immunodeficiency), as per the clinical judgement of the Investigator;
5. Infants with previous, current or intended participation in any other clinical study involving investigational or marketed products;
6. Incapability of infants' parents/legally acceptable representatives to comply with study protocol or Investigator's uncertainty about the willingness or ability of the parent(s)/legally acceptable representative(s) to comply with the protocol requirements;
7. Infants born from mothers with significant medical conditions during pregnancy that might interfere with the study or known to affect intra-uterine growth (e.g. placenta previa, pre-eclampsia, eclampsia, gestational diabetes requiring insulin or oral medication) as per Investigator's judgement.
Criteria for lactating mothers of subjects in the breastfed reference arm:
8. Lactating women who are currently participating or intend to participate in any other clinical study involving investigational products. Participation in purely observational studies is permitted;
9. Lactating women known to suffer from hepatitis B or human immunodeficiency virus;
10. Lactating women known to have any other significant medical condition(s) which might interfere with the study or its outcome parameters (breast abscess or mastitis which could interfere with lactation, or other clinically relevant infections, or consumption of medication/substances which could impact the infants' growth), as per the clinical judgement of the Investigator;
11. Lactating women who intend to feed their infants with a combination of human milk and infant formula.
1 Day
14 Days
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Nutricia Research
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Poliklinika Ginekologiczno-Położnicza Sp. z o.o. Sp. k.
Bialystok, , Poland
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
M Arciszewska
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EBB17TA14644
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.